BioVie targets neuroinflammation and insulin resistance in Parkinson’s treatment approach

BioVie CEO Cuong Do joined Steve Darling from Proactive to discuss the company’s novel approach to treating Parkinson’s disease, focusing on neuroinflammation and insulin resistance as key drivers of the condition. Do challenged the traditional view of Parkinson’s as solely a dopamine-related disorder, explaining that inflammation in the brain may play a more fundamental role. He noted that insulin resistance can impair the ability of brain cells to access glucose, stating, “If you have inflammation, the inflammation acts like rust on that lock… and therefore the door stays closed and glucose cannot get in.” This lack of energy in neurons may contribute significantly to disease progression. BioVie’s lead drug candidate, Bezisterim, is designed to target these underlying mechanisms. According to Do, clinical trials have shown that patients receiving the therapy experienced reductions in neuroinflammation along with improvements in insulin sensitivity. Earlier studies combining Bezisterim with Levodopa also demonstrated enhanced muscle control compared to standard treatment alone. The company is now advancing a new clinical trial evaluating Bezisterim as a standalone therapy in early-stage Parkinson’s patients. The study is designed to assess both motor and non-motor symptoms, including sleep, anxiety, and depression. With enrollment now complete, BioVie is targeting a topline data readout before the end of June, marking an important near-term catalyst for the program. proactiveinvestors #biovieince #nasdaq #bivi #NeurodegenerativeDiseases #parkinsonsdisease #BrainHealth #BioVie #CognitionImprovement #Neuroinflammation #SocialImpact #ElderlyCare #Neuroscience #HealthCrisis #DementiaSupport #BrainScience #GlobalHealth #InsulinResistance #Biotech #DrugDevelopment #ClinicalTrials #Bezisterim #CNSResearch #Neuroscience #HealthcareInnovation #MedicalResearch #Biopharma #Neurodegeneration #ToplineData